SavedAdd your journal

Journals / Nöropsikiyatri Arşivi / 2007 / Cilt: 44 - Sayı: 3

Depression after the usage of topical beta blocker: A case report

Topikal beta bloker kullanımı sonrası gelişen depresif bozukluk: Bir olgu

Aziz YAŞAN
Uğur KEKLİKÇİ
Yusuf TAMAM
Kaan ÜNLÜ
Pages
124–126
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, development of depression can be prevented in patients who use topical beta blocker with a careful follow-up.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Topical beta blockers are commonly used in glaucoma treatment.
📊
Key Findings & Data:Complaints of depression appeared on the 4th day of the topical beta blocker for glaucoma.
💡
Conclusion & Impact:Therefore, development of depression can be prevented in patients who use topical beta blocker with a careful follow-up.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Betaksolol · İlaç uygulama · topikal

Abstract

Topical beta blockers are commonly used in glaucoma treatment. The aim of this study is to discuss the development of the depression after the usage of topical beta blocker and treatment in glaucoma patients. Thirty seven year-old woman who had no episode of depression previously was evaluated after the usage of topical beta blocker. Complaints of depression appeared on the 4th day of the topical beta blocker for glaucoma. Complaints of the patient diminished quickly after the interruption of the topical beta blocker. An additional treatment was not needed for depression. Depression may be related with the use of the topical beta blockers which are used in glaucoma patients. Therefore, development of depression can be prevented in patients who use topical beta blocker with a careful follow-up.

Özet

Glokom tedavisinde topikal beta bloker yaygın bir şekilde kullanılmaktadır. Bu çalışmada amacımız glokomlu hastalarda topikal beta bloker kullanımı sonrası depresif bozukluk gelişimi ve tedaviyi tartışmaktır. Önceden depresyon epizodu olmayan ve bir topikal beta bloker olan betaksolol kullanımından sonra depresif bozukluk gelişen 37 yaşındaki kadın olgu değerlendirildi. Glokom tedavisi için kullanılan topikal beta blokerin 4. gününde depresif yakınmaları başlamıştı. Hastanın depresif şikayetleri topikal beta bloker kesildikten sonra hızla düzelmeye başladı. Depresif şikayetleri için ilave bir tedavi gerekmedi. Glokom tedavisinde kullanılan beta blokerler depresif bozukluk ile ilişkili olabilir. Bu nedenle topikal beta bloker kullanan hastalar dikkatle takip edilip depresif bozukluğunun gelişimi önlenebilir.

🔖

Cite This Article

YAŞAN, A., KEKLİKÇİ, U., TAMAM, Y., ÜNLÜ, K. (2007). Depression after the usage of topical beta blocker: A case report. Nöropsikiyatri Arşivi, Cilt: 44 - Sayı: 3, 124–126. https://ajindex.com/articles/292779

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (20)

  1. Konstas AG, Maskaleris G, Gratsonidis S, et al. Compliance andviewpoint of glaucoma patients in Greece. Eye 2000;14:752-6
  2. Zimmerman TJ, Zalta AH. Facilitating patient compliance inglaucoma therapy. Surv Ophthalmol 1983;28:252-8
  3. Lee MD, Fechtner FR, Fiscella RG, et al. Emergingperspectives on glaucoma: highlights of a roundtable discussion. Am J Ophthalmol 2001;130:1-11
  4. Khaw PT, Shah P, Elkington AR. Glaucoma-2: treatment. BMJ 2004; 328:156-8
  5. Crick PR. Epidemiology and screening of open-angle glaucoma. Curr Opin Ophthalmol 1994;5:3-9
  6. Schweitzer I, Maguire K, Tuckwell V. Antiglaucoma medication and clinical depression. Aust N Z J Psychiatry 2001;35:569-71
  7. Ashburn FS, Goldberg I, Kass MA. Compliance with ocular therapy. Surv Ophthalmol 1980;24:237-48
  8. Davidson SI, Akingbehin T. Compliance in ophthalmology. Trans Ophthalmol Soc U K 1980; 00:286-90
  9. Granstrom PA, Norell S. Visual ability and drug regimen: relation tocompliance with glaucoma therapy. Acta Ophthalmol1983;61:206-19
  10. McMahon CD, Shaffer RN, Hoskins HD, et al. Adverse effects experienced by patients taking timolol. Am J Ophthalmol 1979;88:736-8
  11. Shore JH, Fraunfelder FT, Meyer SM. Psychiatric side-effects from topical ocular timolol, a beta-adrenergic blocker. J Clin Psychopharmacol 1987;7:264-7
  12. Kass M. Non-compliance to ocular therapy: glaucoma report. Ann Ophthalmol 1978;10:1244
  13. Olander K, Zimmerman TJ. Practical aspects of controlling glaucomamedically or how to make your glaucoma medicines work for you Glaucoma editorial. Ann Ophthalmol 1980;85:225
  14. Polk IJ. Drug compliance in the elderly. JAMA 1982;248:1239
  15. Artigas F, Celada P, Laruella M, et al. How does pindolol improve antidepresant action? Trend Pharmacol Sci 2001;222-4
  16. Kaiserman I, Kaiserman N, Elhayany A, et al. Topical-Blockers Are Not Associated with an Increased Risk of Treatmentfor Depression. Ophthalmology 2006;113:1077-80
  17. Brody BL, Gamst AC, Williams RA, et al. Depression, visual acuity, comorbidity, and disabilityassociated with age-related macular degeneration. Ophthalmology 2001;108:1893-900
  18. Wilson MR, Coleman AL, Yu F, et al. Depression in patients with glaucoma as measured byself-report surveys. Ophthalmology 2002;109:1018-22
  19. Cumurcu BE, Cumurcu T, Çelikel FÇ, et al. Glokomlu Hastaların Psikiyatrik Açıdan Değerlendirilmesi. Yeni Symposium Dergisi 2007; 45: 8-13
  20. Ko DT, Hebert PR, Coffey CS. Beta-blocker therapy and symptoms of depression, fatigu